Rx only · Injection, Solution · Intravenous

Neostigmine Methylsulfate

3 ACTIVE SUPPLIERS — US

openFDA · updated weekly

US8 NDCs
3 active makers

UKComing
soon

CAComing
soon

AUComing
soon

EUComing
soon

ATC—

RxCUI (US)—

US makers3 labelers

Packages10

DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

572

Rx · 2026 Q1

2.5K

Units dispensed

-59%

Rx vs. year ago

Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Labeler	Type	Packages	Status
Fresenius Kabi USA, LLC	unknown	7	SUPPLYING
Sagent Pharmaceuticals	unknown	2	SUPPLYING
Dr.Reddy's laboratories Limited	unknown	1	SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

Jan 12, 2026
RESOLVEDShortage resolved: Neostigmine Methylsulfate Injection (Fresenius Kabi USA, LLC)
Neostigmine Methylsulfate Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Analgesia/Addiction.
Jan 12, 2026
SHORTAGEDrug shortage: Neostigmine Methylsulfate Injection (Fresenius Kabi USA, LLC)
Neostigmine Methylsulfate Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Analgesia/Addiction.